ArticleCancers2019

Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study).

Sandor Schokker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.